201 related articles for article (PubMed ID: 18645671)
1. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
Mejía A; Salas W
Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
[TBL] [Abstract][Full Text] [Related]
2. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
5. [Updated cervical cancer screening; human papilloma virus and Papanicolaou tests].
Sasagawa T
Rinsho Byori; 2009 Sep; 57(9):905-12. PubMed ID: 19860220
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
7. [Cost effectiveness of cervical cancer screening strategies in Tunisia].
Hsaïri M; Fakhfakh R; Ghyoula M; Ben Abdallah M; Achour N
Tunis Med; 2000 Oct; 78(10):557-61. PubMed ID: 11190738
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
[TBL] [Abstract][Full Text] [Related]
10. Cost of screening for cancerous and precancerous lesions of the cervix.
Méréa E; Le Galès C; Cochand-Priollet B; Cartier I; de Crémoux P; Vacher-Lavenu MC; Vielh P; Coste J
Diagn Cytopathol; 2002 Oct; 27(4):251-7. PubMed ID: 12357505
[TBL] [Abstract][Full Text] [Related]
11. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Levin CE; Sellors JW
Cancer; 2002 Apr; 94(8):2312-4; author reply 2314-6. PubMed ID: 12001136
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of cervical-cancer screening in developing countries.
Suba EJ; Frable WJ; Raab SS
N Engl J Med; 2006 Apr; 354(14):1535-6; author reply 1535-6. PubMed ID: 16598056
[No Abstract] [Full Text] [Related]
13. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
Perovic S
J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
[TBL] [Abstract][Full Text] [Related]
14. Modeling cost-effectiveness of cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer prevention for all the world's women: genuine promise resides in skilled quality management rather than novel screening approaches.
Suba EJ; Donnelly AD; Furia LM; Huynh ML; Raab SS;
Diagn Cytopathol; 2007 Mar; 35(3):187-91. PubMed ID: 17304532
[TBL] [Abstract][Full Text] [Related]
16. [Cervix cancer screening can be cost-effective. Combination of vaginal smears and the HPV test should be even more beneficial].
Bistoletti P; Ellström A; Dillner J; Sennfält K; Sparén P; Strander B
Lakartidningen; 2005 Jun 13-26; 102(24-25):1874-6, 1878-9. PubMed ID: 16044766
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
Kulasingam SL; Myers ER; Lawson HW; McConnell KJ; Kerlikowske K; Melnikow J; Washington AE; Sawaya GF
Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
19. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
[TBL] [Abstract][Full Text] [Related]
20. Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?
Reust CE
J Fam Pract; 2001 Feb; 50(2):175. PubMed ID: 11219567
[No Abstract] [Full Text] [Related]
[Next] [New Search]